AILBRY - Article Search
Serach over 250 million academic articles from all areas of study
Results for 'Jean‐Yves Pierga'
:
Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
Publication Year: 2022
DOI: https://doi.org/10.1158/1538-7445.sabcs21-pd8-02
Abstract:
Add to Library
Authors:
Véronique Dièras
Élise Deluche
Amélie Lusque
Barbara Pistilli
Thomas Bachelot
Jean‐Yves Pierga
F. Viret
Christelle Lévy
Laura Salabert
Fanny Le Du
Florence Dalenc
Christelle Jouannaud
Laurence Vénat-Bouvet
Jean-Philippe Jacquin
Xavier Durando
Thierry Petit
Céline Mahier - Aït Oukhatar
Thomas Filleron
M.F. Mosele
Magali Lacroix‐Triki
Agnès Ducoulombier
Fabrice André
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-gs3-00
Abstract:
Add to Library
Authors:
Kevin Kalinsky
William E. Barlow
Funda Meric‐Bernstam
Julie R. Gralow
Kathy S. Albain
Daniel F. Hayes
Nancy U. Lin
Edith A. Perez
Lori J. Goldstein
Stephen Chia
Subkhbinder Dhesy-Thind
Priya Rastogi
Emilio Alba
Suzette Delaloge
Miguel Martín
Miguel Gil Gil
Claudia Arce-Salinas
Étienne Brain
In Hae Park
Jean‐Yves Pierga
Ana Hernandez Lluch
Manuel Ramos Vasquez
Manuel Ruíz Borrego
Kyung Hae Jung
Jean-Marc Ferrero
Anne F. Schott
S. Shak
Priyanka Sharma
Danika L. Lew
Jieling Miao
Debu Tripathy
Gabriel N. Hortobágyi
Lajos Pusztai
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study
Publication Year: 2016
DOI: https://doi.org/10.18632/oncotarget.7612
Abstract:
Add to Library
Authors:
Émeline Tabouret
François Bertucci
Jean‐Yves Pierga
Thierry Petit
Christelle Lévy
Jean-Marc Ferrero
Mario Campone
Joseph Gligorov
Florence Lerebours
Henri Roché
Thomas Bachelot
Steven Van Laere
Naoto T. Ueno
Yves Toiron
Pascal Finetti
Daniel Birnbaum
Jean‐Paul Borg
Patrice Viens
Olivier Chinot
Anthony Gonçalvès
Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating <i>ESR1</i> mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial
Publication Year: 2022
DOI: https://doi.org/10.1158/1538-7445.sabcs21-gs3-05
Abstract:
Add to Library
Authors:
François‐Clément Bidard
Anne‐Claire Hardy‐Bessard
Thomas Bachelot
Jean‐Yves Pierga
Jean-Luc Canon
Florian Clatot
Fabrice André
Thibault De La Motte Rouge
Barbara Pistilli
Florence Dalenc
Nadine Dohollou
Olivier Arsène
Thierry Petit
Cécilia Riedl
F. Morvan
Adina Marti
Emma Lachaier
Mihaëla Achille
M. Gozy
Anne Escande
Dominique Mille
Fanny Trouboul
Laurent Arnould
Ivan Bièche
Anne Pradines
Jérôme Lemonnier
Frédérique Berger
Suzette Delaloge
Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with <i>BRCA1/2</i> Inactivation
Publication Year: 2012
DOI: https://doi.org/10.1158/0008-5472.can-12-1470
Abstract:
Add to Library
Authors:
Tatiana Popova
Élodie Manié
Guillaume Rieunier
Virginie Caux‐Moncoutier
Carole Tirapo
Thierry Dubois
Olivier Delattre
Brigitte Sigal‐Zafrani
Marc A. Bollet
Michel Longy
Claude Houdayer
Xavier Sastre‐Garau
Anne Vincent‐Salomon
Dominique Stoppa‐Lyonnet
Marc‐Henri Stern
Abstract CT039: Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes
Publication Year: 2016
DOI: https://doi.org/10.1158/1538-7445.am2016-ct039
Abstract:
Add to Library
Authors:
Martine Piccart
Emiel J. Rutgers
Laura van ‘t Veer
Leen Slaets
Suzette Delaloge
Giuseppe Viale
Jean‐Yves Pierga
Peter Vuylsteke
Étienne Brain
Suzan Vrijaldenhoven
Peter A. Neijenhuis
Bruno Coudert
Tineke J. Smilde
Miguel Gil Gil
Alastair M. Thompson
Isabel T. Rubio
Rodolfo Passalaqua
Erika Matos
U. Nitz
Mauro Delorenzi
Geraldine Thomas
Theodora Goulioti
Carolyn Straehle
Konstantinos Tryfonidis
Jan Bogaerts
Fátima Cardoso
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the <i>FGFR2</i> locus and estrogen receptor status to HER2-negative breast cancer patients
Publication Year: 2016
DOI: https://doi.org/10.18632/oncotarget.12669
Abstract:
Add to Library
Authors:
David G. Cox
Elsa Curtit
Gilles Romieu
P. Fumoleau
María Rios
Hervé Bonnefoi
Thomas Bachelot
P Soulié
Christelle Jouannaud
Hugues Bourgeois
Thierry Petit
Isabelle Tennevet
David Assouline
Marie‐Christine Mathieu
Jean-Philippe Jacquin
Sandrine Lavau‐Denès
Ariane Darut‐Jouve
Jean-Marc Ferrero
Carole Tarpin
Christelle Lévy
Valérie Delecroix
V. Trillet-Lenoir
Oana Cojocarasu
Jérôme Meunier
Jean‐Yves Pierga
Céline Faure-Mercier
Hélène Blanche
Mourad Sahbatou
Anne Boland
Delphine Bacq
Céline Besse
Jean‐François Deleuze
Iris Pauporté
Gilles Thomas
Xavier Pivot
Abstract PD13-12: PD13-12 Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-pd13-12
Abstract:
Add to Library
Authors:
Komal Jhaveri
Hwei-Chung Wang
X. Cynthia
Elgene Lim
Jessica J. Tao
Luís Manso
Jean‐Yves Pierga
Ritesh Parajuli
Yolanda Jerez Gilarranz
Yen‐Shen Lu
Muralidhar Beeram
Tim Larson
Ajay Dhakal
Roohi Ismail-Khan
Claudia Karacsonyi
Shanshan Cao
Cynthia R. Osborne
Shawn T. Estrem
Bastien Nguyen
Yujia Li
Eunice Yuen
Abstract 3390: Predictive and prognostic value of circulating tumor DNA (ctDNA) compared to circulating tumor cells (CTC) in a prospective cohort of metastatic breast cancer patients: The UCBG COMET trial
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.am2020-3390
Abstract:
Add to Library
Authors:
Jean‐Yves Pierga
Amanda Bartolini Silveira
Elodie Girard
Véronique Lorgis
Marie‐Laure Tanguy
Benoît Albaud
Olivier Trédan
Coraline Dubot
Caroline Hego
William Jacot
Anthony Gonçalvès
Marc Debled
Christelle Lévy
Jean-Marc Ferrero
Christelle Jouannaud
Marie‐Ange Mouret‐Reynier
Florence Dalenc
Sylvain Baulande
Jérôme Lemonnier
Frédérique Berger
François‐Clément Bidard
Charlotte Proudhon
Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) ≤ 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)
Publication Year: 2022
DOI: https://doi.org/10.1158/1538-7445.sabcs21-gs2-07
Abstract:
Add to Library
Authors:
Kevin Kalinsky
William E. Barlow
Julie R. Gralow
Funda Meric‐Bernstam
Kathy S. Albain
Daniel F. Hayes
Nancy U. Lin
Edith A. Perez
Lori A Goldstein
Stephen Chia
Sukhbinder Dhesy‐Thind
Priya Rastogi
Emilio Alba
Suzette Delaloge
Miguel Martı́n
Catherine M. Kelly
Manuel Ruíz‐Borrego
Miguel Gil‐Gil
Claudia Arce-Salinas
Étienne Brain
Eun Sook Lee
Jean‐Yves Pierga
Begoña Bermejo
Manuel Ramos-Vasquez
Kyung Hae Jung
Jean-Marc Ferrero
Anne F. Schott
Steven Shak
Priyanka Sharma
Danika L. Lew
Jieling Miao
Debasish Tripathy
Lajos Pusztai
Gabriel Hortobagyi
Abstract 2410: Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for metastatic breast cancer patients: the STIC CTC METABREAST trial.
Publication Year: 2013
DOI: https://doi.org/10.1158/1538-7445.am2013-2410
Abstract:
Add to Library
Authors:
Jean‐Yves Pierga
Sandrine Baffert
David Hajage
Étienne Brain
Sébastien Armanet
Cécile Simondi
L. Mignot
Bernard Asselain
Patricia Tresca
François‐Clément Bidard
Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma <i>In situ</i> of the Breast
Publication Year: 2008
DOI: https://doi.org/10.1158/1078-0432.ccr-07-1465
Abstract:
Add to Library
Authors:
Anne Vincent‐Salomon
Carlo Lucchesi
Nadège Gruel
Virginie Raynal
Gaëlle Pierron
Rémi Goudefroye
Fabien Reyal
François Radvanyi
Rémy Salmon
Jean Paul Thiery
Xavier Sastre‐Garau
Brigitte Sigal‐Zafrani
A. Fourquet
Olivier Delattre
Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-pd4-07
Abstract:
Add to Library
Authors:
Antoinette R. Tan
Seock‐Ah Im
André Mattar
Rámón Colomer
Daniil Stroyakovskii
Zbigniew Nowecki
Michelino De Laurentiis
Jean‐Yves Pierga
Kyung Hae Jung
Christian Schem
Sarah Heeson
Mahesh Shivhare
Whitney P. Kirschbrown
Eleonora Restuccia
Tanja Badovinac Črnjević
Christian Jackisch
Abstract 4599: Detecting MSI phenotype in circulating blood DNA
Publication Year: 2018
DOI: https://doi.org/10.1158/1538-7445.am2018-4599
Abstract:
Add to Library
Authors:
Marc‐Henri Stern
Amanda Bartolini Silveira
Ivan Bièche
Samia Melaabi
Luc Cabel
Bruno Buecher
Jean‐Yves Pierga
François‐Clément Bidard
Charlotte Proudhon
Abstract A50: Circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) for monitoring and predicting response to neoadjuvant therapy (NAT) in high-risk early breast cancer patients in the I-SPY 2 TRIAL
Publication Year: 2020
DOI: https://doi.org/10.1158/1557-3265.liqbiop20-a50
Abstract:
Add to Library
Authors:
Mark Jesus M. Magbanua
Wen Li
Denise M. Wolf
Christina Yau
Gillian L. Hirst
Lamorna Brown Swigart
A. Jo Chien
Amy L. Delson
Jessica Gibbs
Alexey Aleshin
Bernhard Zimmerman
Laura Esserman
Nola Hylton
Laura van ‘t Veer
Found 90 results in 0.159 seconds
What is Boolean Searches
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE . You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Example Search
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"